

## RESIGNATION OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

**BRISBANE, AUSTRALIA, 9 JANUARY 2026:** AnteoTech Ltd (ASX: ADO) (**'AnteoTech'** or **'the Company'**) advises that Mr. Andrew Cook has tendered his resignation from his roles as Chief Financial Officer and Company Secretary in order to pursue other business interests.

The Board thanks Mr. Cook for his contribution to AnteoTech during his tenure and wishes him the very best in his future endeavours.

AnteoTech will undertake a process to identify Mr. Cook's successor and will progress an orderly transition, under Mr Cook's employment contract terms.

Further updates regarding interim arrangements and permanent appointments will be provided in due course.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries: on +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)**

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check out our website [www.anteotech.com](http://www.anteotech.com).

## About AnteoTech - (ASX:ADO)

AnteoTech is a supplier of chemicals and advanced material solutions to the Lithium-ion Battery (LiB) and Life Sciences markets globally. Here we leverage our market leading surface modification and binding chemical platform technology to develop and commercialise solutions for global customers. From our patented high silicon anode cross linking product, Anteo X™ and LiB Separator binder Anteo S to our next generation LiB high silicon anode formulations, Ultranode™, our Advanced Battery Materials business applies its unique materials science, chemistry and engineering expertise to address the growing demand for high performance, low cost, sustainable and readily supply chain accessible materials in high silicon LiBs across the global market. Our Life Sciences business delivers improved bioconjugation and advanced surface activation to materials for use in in vitro diagnostics, in the immunoassays market, through our AnteoBind™ suite of products. The Life Sciences business works with customers across the Lateral flow, Luminex, Chemiluminescence (CLIA) and enzyme linked immunosorbent assay (ELISA) sectors. Where our products enable faster, more reliable, more cost effective and accurate test results wherever they are needed.

## AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’ business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.